MTOR and neoplasm: Additionally, elevated expression of CCL2 in gefitinib-resistant cell lines facilitates the recruitment of M2-type macrophages and activates the AKT/mTOR signaling pathway, thereby diminishing gefitinib’s anti-tumor efficacy [80].